For the latest updates on how we are managing changes due to COVID-19 please click here.

Biocube allergen chamber study to start for new therapeutic for rhinitis indication

Initiating March 29, 2015 is a clinical trial for the treatment of allergic rhinitis for 3E Therapeutics Corporation, using an innovative drug therapy and Ora’s proprietary exposure chamber unit, the fully validated Allergen BioCube. The BioCube is both a stationary and mobile state-of-the-art allergen exposure chamber developed by Ora. The Biocube releases calibrated quantities of pollen with precise and reproducible techniques.  The delivery of  aeroallergens to each patient is verified by real time Laser Detection of the particulates in the air.  Turning an ISO class 3 clean-room into a controlled allergy environment, the BioCube is validated to produce clinical results.

Different from other chamber models, subjects exposed to pollen in the BioCube experience the signs and symptoms of nasal allergy in a manner identical to pollen exposure in the environment.

3E Therapeutics Corporation is a private company dedicated to the development of safe new treatments for allergic rhinitis, allergic conjunctivitis, and other illnesses. The company has been operating since 2013 to advance drug development programs through pre-clinical and clinical stages. 3E is located in La Jolla, California.

3E’s Nasapaque topical nasal solution has the potential for a more rapid onset of action than allergic rhinitis drugs currently on the market because of Nasapaque’s unique mechanism of action. Nasapaque is also expected to show a high level of safety, based on preliminary studies. In this randomized, double-masked placebo-controlled clinical trial, adult subjects will be exposed to approved and validated levels of allergenic ragweed in the BioCube. The primary efficacy endpoint will be Total Nasal Symptom Score (TNSS). Nasal endoscopic images of the inferior turbinate will be captured and an objective measure of nasal congestion derived as an additional endpoint. For more information, see (Study NCT02377895).